Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
It plans to double its network to 50 centres across India in the next three years
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Cipla has reported consolidated financial results for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Subscribe To Our Newsletter & Stay Updated
